STOCK TITAN

Zai Lab (ZLAB) CFO sells ADS under 10b5-1 trading plan

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Zai Lab Ltd (ZLAB) reported that its Chief Financial Officer, Chen Yajing, sold 260 American Depositary Shares (ADS) of the company on 2026-08-19 at $27.00 per ADS. Following this sale, Chen directly holds 35,635 ADS. Each ADS represents ten Ordinary Shares, and the ADSs and Ordinary Shares are described as fully fungible. The sale was effected under a Rule 10b5-1 trading plan adopted on December 9, 2025.

Positive

  • None.

Negative

  • None.
Insider Chen Yajing
Role Chief Financial Officer
Sold 260 shs ($7K)
Type Security Shares Price Value
Sale American Depositary Shares F1, F2 260 $27.00 $7K
Holdings After Transaction: American Depositary Shares — 35,635 shares (Direct)
Footnotes (2)
  1. F1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
  2. F2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
ADS sold 260 American Depositary Shares Non-derivative sale on 2026-08-19 by CFO Chen Yajing
Sale price per ADS $27.00 per American Depositary Share Price for the 2026-08-19 sale transaction
Holdings after transaction 35,635 American Depositary Shares Directly held by Chen Yajing after the reported sale
ADS to Ordinary Share ratio 1 ADS = 10 Ordinary Shares Each ADS represents ten Ordinary Shares of Zai Lab Ltd
Rule 10b5-1 adoption date December 9, 2025 Adoption date of trading plan governing the reported sale
American Depositary Shares financial
"Each American Depositary Share ("ADS") represents ten Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Rule 10b5-1 trading plan regulatory
"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
fully fungible financial
"Our ADSs and Ordinary Shares are fully fungible."

FAQ

What insider transaction did ZLAB report for Chen Yajing?

Zai Lab Ltd reported that Chief Financial Officer Chen Yajing sold 260 ADS on 2026-08-19 at $27.00 per ADS, leaving her with 35,635 ADS directly held.

At what price were the ZLAB ADS sold in this Form 4?

The reported sale of Zai Lab Ltd (ZLAB) securities was executed at a price of $27.00 per American Depositary Share (ADS) on 2026-08-19.

How many ZLAB shares does Chen Yajing hold after this transaction?

After the reported sale, Chief Financial Officer Chen Yajing directly holds 35,635 American Depositary Shares (ADS) of Zai Lab Ltd.

What does one ZLAB American Depositary Share represent?

Each Zai Lab Ltd American Depositary Share (ADS) represents ten Ordinary Shares. The filing states that the company’s ADSs and Ordinary Shares are fully fungible.

Was the ZLAB insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chen Yajing

(Last)(First)(Middle)
C/O ZAI LAB LIMITED
314 MAIN STREET, 4TH FLOOR, SUITE 100

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Zai Lab Ltd [ ZLAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American Depositary Shares(1)08/19/2026S(2)260D$2735,635D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
/s/ Bruce Blefeld, Attorney-in-Fact08/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)